Compare Becton Dickinson and Co (BDX) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while iShares 20 Plus Year Treasury Bond ETF trades at $83.86. The key difference: Becton Dickinson and Co pays a 2.79% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and Becton Dickinson and Co is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BDX | TLT | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | — |
52-Week High | $185.39 | $92.06 |
52-Week Low | $135.49 | $83.02 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TLT trades at $83.97, down 0.59% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as fixed income sees renewed interest amid economic uncertainty. Recent dividend payments of $0.32-$0.34 highlight income generation, while technical indicators show oversold conditions with RSI at 27.67 suggesting potential rebound opportunity.
Long-term Treasury bonds offer attractive yields but face interest rate sensitivity. The Fed's hawkish stance presents near-term headwinds, though TLT's 4-5x higher starting yields than pre-crisis levels provide income appeal. Investors must weigh duration risk against potential Fed policy shifts and inflation trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
